Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019 12 10; 3(23):4136-4146.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.